Australia's newest biotech incubator is calling for innovative early-stage Australian biotechs to take up residency in its much-awaited Melbourne-based facility.

The Jumar Bioincubator will be supported by cash and in-kind contributions of approximately $45 million over ten years from its founding partners, global biotech leader CSL, WEHI, and The University of Melbourne, as well as an initial investment of $25 million from Breakthrough Victoria.

The incubator will connect early-stage and scaling biotech ventures with state-of-the-art facilities, infrastructure, and support needed to progress discoveries towards real-world treatments, while enhancing the opportunity to commercialise medical research. 

The incubator, which cost $30 million to build, will facilitate research commercialisation and innovation translation by providing biomedical scientists and researchers with access to knowledge and skills needed to run successful biomed and biotech companies.

Jumar is Australia's first and only biotech incubator to be co-located with a leading biopharmaceutical company in a world-class biomedical precinct. Jumar will be located across two floors of CSL's new Global Headquarters and Centre for R&D in the Melbourne Biomedical Precinct when it opens its doors in September 2023.